PERFLUTREN


Trade Names	DEFINITY
Synonyms	DMP 115 DMP-115 Definity Definity rt FS-069 FS069 MRX-115 Perfluoropropane Perflutren
Status
Molecule Category	UNKNOWN
UNII	CK0N3WH0SR
EPA CompTox	DTXSID9052503


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QYSGYZVSCZSLHT-UHFFFAOYSA-N
Smiles	FC(F)(F)C(F)(F)C(F)(F)F
InChI	InChI=1S/C3F8/c4-1(5,2(6,7)8)3(9,10)11

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C3F8
Molecular Weight	188.02
AlogP	2.75
Hydrogen Bond Acceptor	0.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	0.0
Polar Surface Area	0.0
Molecular species	None
Aromatic Rings	0.0
Heavy Atoms	11.0

Bioactivity

Mechanism of Action	Action	Reference
Diagnostic agent	None	FDA

Related Entries

Cross References

Resources	Reference
ChEBI	31980
ChEMBL	CHEMBL1663
DrugBank	DB00556
DrugCentral	2104
FDA SRS	CK0N3WH0SR
Human Metabolome Database	HMDB0014696
PharmGKB	PA164781354
PubChem	6432
SureChEMBL	SCHEMBL34348
ZINC	ZINC000008214651

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).